Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:ef46:0:b0:441:282b:bd with SMTP id c6csp1526846wrp; Mon, 4 May 2026 15:07:35 -0700 (PDT) X-Received: by 2002:a05:622a:54e:b0:50f:be4f:465d with SMTP id d75a77b69052e-5104bf50838mr163008331cf.46.1777932454886; Mon, 04 May 2026 15:07:34 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1777932454; cv=none; d=google.com; s=arc-20240605; b=DQEci86bsG0UgkvChMnJ5hfDNgJCzQTBNDIN/yrJR4nTR/OS/1XvU9pOET8mxoleRf FRNX2viQpWkTsM0fX0OArv5YBsGUb++uXDdMQaYwaBN1D8M7NFK5HpDWFVdy/gL8osQP 4UAdH3gOVoC8ZhQI9xUcE6m1UMSJLvw/tUTd4cXseT0yPdlf033s0BB4K2cvxQOqKEP8 bOxpB/C0nJtND4AzU6FlQyyoe6RklKNHbg24hZ//hxHq9T/p04Mm9fqxqie7PLqsnO/M Pt94JGpWoMVVlrpAOiv6/yGoYKXqoWBO79zIItBy1geeT9LsDYgy11jPU0JAWimjMlI/ wWug== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=message-id:date:mime-version:sid:subject:reply-to :list-unsubscribe-post:list-unsubscribe:from:feedback-id:to :dkim-signature:dkim-signature; bh=wu54lI2J5lbsBIY4u3OF8el/79QPr/02bMMveGSJCbg=; fh=Hcu5VqhndQNvtVhwbc8tr7JrSOSQJms/+lG2L+E9gBs=; b=Nm1uCscP5WCIyziKsFErBTkeQO8mmKtYFyU+svaTdd5IexcRsTpPRCbqSxmtThKEfs 96kYwMHd9wtPN+HGMWEbVfv5BQsvpMwMgppO1MPTxYxFK306jED0OkO6/+W0w2qev4w3 Kz54SrQuxOUfcW44NUK6+WWKiLY1IVcTEAXYW73+criv2LZ+hptbSME8J+ZtsJkvfxFr 7k75i8GnR7bwhQM/i7fHdTqFqWJtD6nGsqXSMFcWMxfEu97F4s8kFMPIx86aR31GcR9U Iam4KD8yE2oFkgaHgnekrR7ksLLyoLOfYWOFkqAv8kZFEmtfLVB07lCH1gj4zvsSdz4v Auiw==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=vGALc1zY; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=lSUyEpSs; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.48 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com Return-Path: Received: from bh186-48.smtp-out.beehiivmail.net (bh186-48.smtp-out.beehiivmail.net. [69.67.186.48]) by mx.google.com with ESMTPS id d75a77b69052e-51040b20386si124125341cf.207.2026.05.04.15.07.34 for (version=TLS1_3 cipher=TLS_AES_256_GCM_SHA384 bits=256/256); Mon, 04 May 2026 15:07:34 -0700 (PDT) Received-SPF: pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.48 as permitted sender) client-ip=69.67.186.48; Authentication-Results: mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=vGALc1zY; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=lSUyEpSs; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.48 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com X-BmtaRef: eyJfQF8iOiJcXF8vIiwicmVjaXBpZW50IjoidGpwaHVoc0BnbWFpbC5jb20iLCJ4X2xpc3RfaWQiOiJmZDQxNjMwZS1lOTFmLTQ2ZDktYTI3NC1iNzQwZGFiNzU2ZDIiLCJ4X3N1YnNjcmliZXJfaWQiOiI5YzQwZDYzOS02ZTFkLTQyOTItYTlkNy0wZTRjYmJiNWQ1ZGIifQ== DKIM-Signature: v=1; a=rsa-sha256; d=bhmta.beehiiv.com; s=bh; c=relaxed/relaxed; bh=wu54lI2J5lbsBIY4u3OF8el/79QPr/02bMMveGSJCbg=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1777932341; b=vGALc1zYFn9nYiRU/aJzz/GFNnI5/7Jie3tl69Hj3mR8SQaOjJ40aJ4XwYIlqWsl850i9ZDzt 2kLygaCJifw3289Ll9MaQ8yo+vpqNTWye3tf8fhHByZKuuKqaStvM57T3STnivsWBCoNRAkF+q9 3M1EmV7BtvI88LSSew9kKsrjhaWtPJHZUKHxnAS6P44uDon/GQacafBCtlG/QbnUOR5ZH9mb019 oOpa1mVjpO+b2kuTBuAQ3otoZU1ZCbVbwEluUW6aIiONteDbjyMkYfPA+vD5hg31m6pQl1iwSgE RxKDbzyZDySi6oG5Z0Da/W5D247cfYP0tNCjnUeuJKeA==; DKIM-Signature: v=1; a=rsa-sha256; d=mail.beehiiv.com; s=bh; c=relaxed/relaxed; bh=wu54lI2J5lbsBIY4u3OF8el/79QPr/02bMMveGSJCbg=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1777932341; b=lSUyEpSsOZD1VEk8HhKUOaNDThJp8JxGeYjPEUji1x1ExkWJj6bubxOVId5BkNgelbiR5cNTT ++dk8/8kS+I3DgL2TRGMYTRKkRDPKr8C5gMBvMCu8Pdo6Td4LXmGNKHO/n7oa71lw1j/kfGsEDq 4mEOt9Jjjs7meEMx9pL6rzyRLYJpdXeie6EKtT774xxfC18whP/p1mDFcMcgtl8iCjRgO2LC+xA JGHniETng8JT7mO3yJR3M6befu7mAdyk7VQsCkIN7UMAVwybit0i2kzt2O41Bw8FkUQpPzruv+G QN0dlQXRaZa3YRoUUeh3T3xE3CbaaLZu3lmkpk2bMq3A==; Received: from mail.beehiiv.com by bhmta(mta19) with HTTP id <63b80bcc480511f1991312609588b57b> for ; Mon, 04 May 2026 22:05:41 +0000 Content-Type: multipart/alternative; boundary="yGAsNvxYTpKmWiDp/a7uHQ" To: "tjphuhs@gmail.com" Feedback-ID: c676b4af-ba99-439e-91f1-e5d4cf951913:newsletter:fd41630e-e91f-46d9-a274-b740dab756d2:c8f61fda6a60803 From: Hunter Williams List-Unsubscribe: , List-Unsubscribe-Post: List-Unsubscribe=One-Click Reply-To: =?utf-8?Q?Hunter=27s_Health_Hacks?= Subject: GLP-1s vs. Fertility X-Batch-Id: 3b1965ba-e4a5-4f9d-a31f-f2f7642ba7b0 X-Subscriber-ID: 9c40d639-6e1d-4292-a9d7-0e4cbbb5d5db X-Subscription-ID: 663283104 sId: fd41630e-e91f-46d9-a274-b740dab756d2 x-beehiiv-ids: {"account_name":"https://huntershealthhacks.beehiiv.com/","campaign_id":"c676b4af-ba99-439e-91f1-e5d4cf951913","category":"newsletter","email_generated_at":1777932340,"user_id":"fd41630e-e91f-46d9-a274-b740dab756d2"} x-beehiiv-type: newsletter x-list-id: fd41630e-e91f-46d9-a274-b740dab756d2 x-list-owner: x-newsletter: https://huntershealthhacks.beehiiv.com/p/glp-1s-vs-fertility x-newsletter-id: https://huntershealthhacks.beehiiv.com/ x-newsletter-signup: https://huntershealthhacks.beehiiv.com/subscribe Mime-Version: 1.0 Date: Mon, 4 May 2026 22:05:41 +0000 Message-ID: <20260504.220541.7cde7718@mta19> --yGAsNvxYTpKmWiDp/a7uHQ Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Happy Monday!=0A=0ATaylor and I are trying to have a baby.=0A=0AAs I do wit= h most everything in my life, I research as much as I can to achieve the de= sired outcome. Studies I used to skim now feel much more personal. And the = one that's been on my mind lately is from Dr. Shanna Swan.=0A=0AIf you have= n't read her book _Countdown_, here's the short version. Sperm concentratio= n in Western men decreased by more than 50% between 1973 and 2011. =0A=0ATo= tal sperm count fell almost 60%. Female fertility metrics are following the= same curve. And the rate of decline is accelerating.=0A=0AHer thesis is th= at endocrine-disrupting chemicals are wrecking us. Phthalates in plastics. = BPA in receipts and food packaging. Pesticides. Flame retardants. The expos= ure starts in utero and follows us for life.=0A=0ASwan predicts that by 204= 5, sperm counts could approach zero in the median Western man. Take that wi= th whatever grain of salt you want, but the trajectory alone is enough to t= ake seriously.=0A=0AIt's a bleak read. I'd recommend it anyway.=0A=0AThe ch= emical load is just one piece of the story. The other piece is metabolic dy= sfunction. Obesity, insulin resistance, and type 2 diabetes are now mainstr= eam in adults of reproductive age. All three crush hormones, ovulation, and= gamete quality.=0A=0AThat's where GLP-1 receptor agonists come into play.= =0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=0A=0A**Do GLP-1s Help Fertility?**=0A=0AShort answ= er. Yes. In both sexes.=0A=0AGLP-1 receptors are expressed in male reproduc= tive tissues. Sertoli cells, Leydig cells, and sperm themselves. They're al= so expressed in the ovary. Granulosa cells, theca cells, and the hypothalam= ic neurons that govern reproduction.=0A=0AWhen GLP-1 binds to its receptor,= it activates downstream signaling through cAMP/PKA and PI3K/Akt. These are= the same pathways that regulate spermatogenesis and granulosa cell surviva= l. Recent mechanistic work shows GLP-1R activation also influences FOXO1 ph= osphorylation, which drives granulosa cell proliferation and protects them = from apoptosis.=0A=0AIn plain language, the receptor is hooked into the mac= hinery that makes eggs and sperm.=0A=0AAdd the systemic effects. Lower insu= lin. Lower inflammation. Improved leptin signaling. Better gonadotropin pul= satility. All of which matter for reproduction.=0A=0ASo the mechanism is re= al, but the question is whether the clinical data back it up.=0A=0A=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=0A=0A**The Male Data**=0A=0AIn a 2023 trial, La Vignera and co= lleagues gave liraglutide to obese men with metabolic hypogonadism and seve= re erectile dysfunction. =0A=0AAfter 4 months, semen concentration, motilit= y, and morphology all significantly improved. Erectile function scores impr= oved more than with conventional fertility treatment or testosterone therap= y.=0A=0AIn 2025, Gregori=C4=8D and colleagues ran a randomized trial compar= ing semaglutide 1mg weekly to testosterone replacement in obese men with ty= pe 2 diabetes and functional hypogonadism. After 24 weeks, semaglutide sign= ificantly improved sperm morphology. The TRT group, predictably, suppressed= spermatogenesis.=0A=0AA 2025 systematic review compiled 16 clinical studie= s. The pattern is consistent. GLP-1 therapy raised total testosterone in ob= ese men. Liraglutide improved LH, FSH, and SHBG. Semen quality improved acr= oss concentration, count, motility, and morphology.=0A=0AMany of these bene= fits track with weight loss, not necessarily a direct drug effect. In one c= leaner trial, men who maintained over 11.7kg of weight loss saw the sperm b= enefits regardless of whether they got liraglutide or a placebo.=0A=0ASo is= the GLP-1 doing something to the gonads, or is it just delivering reliable= weight loss in a population that desperately needs it? The animal and mech= anistic data suggest both. =0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**The Female Data*= *=0A=0AThis is where the data gets really interesting.=0A=0AA 2023 meta-ana= lysis in _BMC Endocrine Disorders_ pooled 11 randomized controlled trials c= overing 840 women with PCOS. GLP-1 therapy nearly doubled the natural pregn= ancy rate compared with controls. Menstrual regularity improved significant= ly. Insulin resistance, BMI, waist circumference, and SHBG all improved.=0A= =0AIn a head-to-head trial, exenatide doubled natural pregnancy rates compa= red to metformin in obese PCOS women (43.6% vs 18.7%) over 24 weeks. A 2023= meta-analysis confirmed this pattern across nine RCTs. Exenatide outperfor= med metformin on pregnancy rate, ovulation rate, and androgen reduction.=0A= =0ALiraglutide combined with metformin significantly improved IVF pregnancy= rates in obese PCOS women who had previously failed first-line fertility t= reatments. The combination beat metformin alone.=0A=0AA 2026 systematic rev= iew in the _International Journal of Molecular Sciences_ synthesized clinic= al, animal, and cellular data. The conclusion is that GLP-1 receptor activa= tion directly influences ovarian steroidogenesis, granulosa cell biology, a= nd the FSH-cAMP-BMP signaling pathway. It's likely a direct ovarian effect = layered on top of metabolic improvement.=0A=0A=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**M= icrodosing for Fertility**=0A=0AHere's where I'm going to get speculative. = =0A=0AMost of the GLP-1 fertility research uses standard or high doses. The= kind aimed at meaningful weight loss. 1mg semaglutide weekly. 3mg liraglut= ide daily. Doses big enough to drive 10 to 15% body weight reduction.=0A=0A= But mechanistic work shows that GLP-1 receptor activation is doing useful t= hings in reproductive tissues at signaling levels well below those needed f= or major weight loss. =0A=0AGranulosa cell proliferation. Sertoli cell meta= bolism. Inflammatory tone. Insulin sensitivity. All of these respond to low= er-grade GLP-1 stimulation.=0A=0AMy theory is that a microdose of a GLP-1, = well below the weight-loss range, could deliver the metabolic and signaling= benefits that improve gamete quality without the side-effect burden or the= body-composition swings of full doses.=0A=0AThink of it as turning a dial,= not flipping a switch. You're tuning insulin sensitivity, lowering inflamm= ation, and supporting receptor activity in reproductive tissues. You're not= trying to lose 30 pounds.=0A=0AWe don't have RCTs on microdose GLP-1 for f= ertility specifically. So this is a hypothesis built on mechanism plus dose= -response logic, not a proven protocol. If you go this route, do it with a = knowledgeable provider and accept that you're operating ahead of the publis= hed evidence.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**Final Thoughts**=0A=0ATaylor= and I are both using small doses of a GLP-1 right now.=0A=0ANot because ei= ther of us needs to lose weight. We don't. =0A=0AWe're using it because the= mechanistic data on gamete quality, insulin sensitivity, and inflammation = are compelling enough that I want every advantage I can get going into this= . We definitely don=E2=80=99t plan on using a GLP-1 once she conceives, but= leading up to conception, there is good evidence that it could help with f= ertility. =0A=0AIf Swan is right that we're losing fertility to a combinati= on of environmental load and metabolic dysfunction, we need every tool avai= lable. =0A=0ACleaning up the home, ditching plastic food storage, filtering= water, and eating real food. That's the foundation. Taylor and I do it all= .=0A=0AFor couples whose fertility is being dragged down by metabolic dysfu= nction, GLP-1s are the most promising pharmacological lever I've seen in a = decade. =0A=0AThe female data on PCOS pregnancy rates is the strongest sign= al in the whole literature. The male data is catching up.=0A=0AThe next 24 = months of trial data will tell us a lot. =0A=0AI'll keep you posted on what= we learn, on our journey, and on the science.=0A=0AGLP-1s may in fact be h= umanity=E2=80=99s last hope of avoiding extinction! =0A=0ABest, =0A=0AHunte= r Williams=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**Further Reading**=0A=0A* [https= ://www.shannaswan.com/countdown](https://www.shannaswan.com/countdown)=0A= =0A* [https://pmc.ncbi.nlm.nih.gov/articles/PMC9860933/](https://pmc.ncbi.n= lm.nih.gov/articles/PMC9860933/)=0A=0A* [https://dom-pubs.onlinelibrary.wil= ey.com/doi/10.1111/dom.16042](https://dom-pubs.onlinelibrary.wiley.com/doi/= 10.1111/dom.16042)=0A=0A* [https://pubmed.ncbi.nlm.nih.gov/41016449/](https= ://pubmed.ncbi.nlm.nih.gov/41016449/)=0A=0A* [https://pmc.ncbi.nlm.nih.gov/= articles/PMC10631119/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10631119/)= =0A=0A* [https://pubmed.ncbi.nlm.nih.gov/28834553/](https://pubmed.ncbi.nlm= .nih.gov/28834553/)=0A=0A* [https://pmc.ncbi.nlm.nih.gov/articles/PMC128415= 15/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12841515/)=0A=0A* [https://pm= c.ncbi.nlm.nih.gov/articles/PMC9405922/](https://pmc.ncbi.nlm.nih.gov/artic= les/PMC9405922/)=0A=0A=0A=E2=80=94=E2=80=94=E2=80=94=0A=0AYou are reading a= plain text version of this post. For the best experience, copy and paste t= his link in your browser to view the post online:=0Ahttps://huntershealthha= cks.beehiiv.com/p/glp-1s-vs-fertility --yGAsNvxYTpKmWiDp/a7uHQ Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable GLP-1s vs. Fertility